L-theanine has become one of the most widely used functional ingredients in beverages formulated to support focus, relaxation, and cognitive wellness. As manufacturers continue to expand into ready-to-drink (RTD) beverages, enhanced waters, sports drinks, and other functional products, one regulatory question arises repeatedly: Is L-theanine GRAS?
The answer is yes—but only under specific conditions. FDA has responded with “no questions” to multiple GRAS Notices for L-theanine intended for use in conventional foods and beverages. However, GRAS is not a blanket designation that automatically applies to every commercial L-theanine ingredient or every proposed application. Existing regulatory precedent depends on factors including ingredient identity, manufacturing process, purity, intended food categories, use levels, and estimated dietary exposure. This article examines the current GRAS landscape for L-theanine, reviews existing FDA precedent, and discusses the regulatory considerations manufacturers should evaluate before incorporating L-theanine into beverages intended for the U.S. market.
L-theanine has rapidly evolved from a specialty dietary supplement ingredient into one of the most recognizable functional ingredients used in conventional foods and beverages. Originally associated with green tea, it is now commonly incorporated into products positioned around mental focus, relaxation, stress management, and cognitive wellness.
The growth of the functional beverage market has accelerated this trend. Today’s consumers increasingly seek beverages that provide benefits beyond hydration, leading manufacturers to develop products containing ingredients traditionally found in dietary supplements. Functional waters, sparkling beverages, sports drinks, ready-to-drink teas, powdered drink mixes, and nootropic beverages frequently feature L-theanine alongside other ingredients such as caffeine, electrolytes, botanical extracts, vitamins, and amino acids.
As companies develop these products, one regulatory question consistently arises:
Can L-theanine be legally added to conventional beverages in the United States?
More specifically:
Is L-theanine GRAS?
The short answer is yes—there is significant GRAS precedent supporting certain uses of L-theanine in conventional foods and beverages.
However, the regulatory answer is considerably more nuanced than a simple yes or no.
Unlike a regulatory approval that broadly authorizes an ingredient for any application, a GRAS conclusion applies to a specific ingredient under specific intended conditions of use. Those conditions include the ingredient’s identity, manufacturing process, specifications, intended food categories, use levels, estimated dietary exposure, and intended consumer population.
This distinction is important because not all commercial L-theanine ingredients are manufactured the same way. While some are extracted from tea leaves, others are produced through chemical synthesis or fermentation technologies. Even if the resulting ingredient is chemically identical, differences in manufacturing, specifications, impurity profiles, and proposed uses may influence whether existing GRAS precedent adequately supports the commercial ingredient.
Understanding where existing precedent applies—and where additional regulatory evaluation may be appropriate—can help manufacturers reduce development timelines, support customer confidence, and facilitate successful commercialization.
In the United States, substances intentionally added to conventional foods are generally considered food additives under the Federal Food, Drug, and Cosmetic Act unless an exemption applies. One of the most important exemptions is Generally Recognized as Safe (GRAS).
A substance may be considered GRAS when qualified experts generally recognize, based on scientific procedures—or, for certain ingredients, common use in food before 1958—that the substance is safe under its intended conditions of use.
For modern functional ingredients such as L-theanine, GRAS conclusions are almost always established through scientific procedures, meaning the conclusion is supported by publicly available scientific evidence demonstrating that qualified experts would generally recognize the ingredient as safe for its intended application.
Importantly, GRAS is not a blanket declaration that an ingredient is safe under every circumstance.
Instead, every GRAS conclusion is tied to a defined set of conditions that typically include:
If any of these factors change significantly, manufacturers should evaluate whether existing regulatory precedent still applies.
For example, an ingredient supported for use in beverages at one concentration may not necessarily be supported at substantially higher use levels, in different food categories, or for a different target population.
Self-GRAS vs. FDA Notification
Another common misconception is that FDA “approves” GRAS ingredients.
In reality, GRAS conclusions may be established in two primary ways.
The first is an independent (self-) GRAS conclusion, in which independent qualified experts evaluate the available scientific evidence and conclude that the intended use of an ingredient is generally recognized as safe.
The second involves submitting a GRAS Notice to FDA through the GRAS Notification Program. FDA reviews the notifier’s submission and typically responds in one of several ways, ideally being that the agency has “no questions” regarding the notifier’s conclusion that the substance is GRAS under its intended conditions of use.
This distinction is important.
A “no questions” letter is not an approval by FDA. Rather, it indicates that, based on the information provided, FDA has no questions regarding the notifier’s conclusion. Responsibility for ensuring that an ingredient is safe and lawfully marketed ultimately remains with the manufacturer and other responsible parties throughout the supply chain.
For companies developing functional ingredients or beverages, understanding this distinction helps avoid a common regulatory misunderstanding. Saying an ingredient is “FDA approved” when referring to a GRAS Notice is technically incorrect. Instead, manufacturers should refer to the applicable GRAS conclusion or FDA’s “no questions” response under the specific intended conditions of use.
Several GRAS Notices submitted over the past two decades have established substantial regulatory precedent supporting the use of L-theanine in conventional foods and beverages. Collectively, these notices demonstrate that L-theanine has been evaluated under multiple manufacturing approaches and for a variety of food applications.
Perhaps more importantly, they illustrate an important principle of the GRAS framework: FDA evaluates the specific ingredient being marketed—not simply the ingredient name.
The regulatory history of L-theanine also reflects how ingredient innovation has evolved over time. Early commercial products relied primarily on purified L-theanine, while later notices evaluated tea-derived ingredients, chemically synthesized materials, and more recently, fermentation-derived production methods (FDA Response still pending as of August 2026).
Rather than replacing previous precedent, each GRAS Notice builds upon the regulatory understanding of a specific commercial ingredient and its intended conditions of use.
GRN 209 – Establishing Early GRAS Precedent
One of the earliest publicly available GRAS Notices involving L-theanine (enzymatically driven production process) was GRN No. 209, submitted by Taiyo International, Inc. in 2006.
The notice evaluated L-theanine for use in several conventional food categories at maximum levels of 250 milligrams per serving, corresponding to a 90th percentile of intake 1,284 mg/day.
Following its review, FDA responded that it had no questions regarding the notifier’s conclusion that L-theanine was GRAS under the proposed conditions of use.
This notice established one of the earliest regulatory precedents supporting L-theanine as an ingredient for conventional foods and provided a scientific foundation for future commercial applications.
GRN 338 – Expanding Beverage Applications
In 2010, Blue California submitted GRN No. 338, evaluating L-theanine extracted from tea leaves (Camellia sinensis).
While this notice included identical intended use levels and food categories to GRN 209, the ingredient in GRN 338 was derived from natural sources, rather than an enzymatically catalyzed process.
Once again, FDA responded that it had no questions regarding the notifier’s conclusion that the ingredient was GRAS under its intended conditions of use.
GRN 501 – Chemically Synthesized L-theanine
Regulatory precedent continued to evolve in 2014 when Zhejiang Tianrui Chemical Co., Ltd. submitted GRN No. 501 for chemically synthesized L-theanine.
Although consumers often associate L-theanine exclusively with green tea, commercial production methods have expanded considerably over the years. Chemical synthesis represents one approach to producing highly purified L-theanine intended for food applications.
FDA again responded that it had no questions regarding the notifier’s conclusion that the ingredient was GRAS.
This notice illustrates an important regulatory principle: GRAS evaluations are not limited to botanical sources alone. Instead, they focus on the identity of the commercial ingredient, how it is manufactured, whether appropriate specifications are established, and whether the available scientific evidence adequately supports its intended conditions of use.
GRN 1311 – The Regulatory Landscape Continues to Evolve
Ingredient manufacturing technologies continue to advance, and the GRAS landscape continues to evolve alongside them.
In 2026, Zhejiang Zhenyuan Biotech Co., Ltd. submitted GRN No. 1311 for L-theanine produced by Escherichia coli.
The proposed intended uses include numerous beverage categories such as fruit drinks, sports drinks, energy drinks, enhanced waters, carbonated beverages, and teas, along with several confectionery products.
At the time of writing, FDA has not yet completed its review of this GRAS Notice.
Although the notice demonstrates the continued evolution of commercial manufacturing technologies, manufacturers should not assume that fermentation-derived L-theanine is supported by the same regulatory precedent as previously reviewed ingredients until FDA’s review process has concluded.
The pending notice nevertheless illustrates an important trend: as ingredient manufacturing technologies evolve, companies continue to evaluate new production methods through the GRAS framework rather than assuming existing precedent automatically applies.
One of the most important lessons from the regulatory history of L-theanine is that GRAS applies to a specific commercial ingredient—not merely to the name “L-theanine.”
At first glance, this distinction may seem unnecessary. After all, L-theanine is a single chemical compound regardless of whether it originates from tea leaves, chemical synthesis, or fermentation.
However, from a regulatory perspective, manufacturing is about much more than the final molecular structure.
Different production methods may introduce differences in:
These characteristics help define the commercial ingredient being evaluated and influence whether the available scientific evidence adequately supports its intended use.
The progression from GRN 209 to GRN 338, GRN 501, and the pending GRN 1311 illustrates this principle clearly. Rather than relying on a single historical precedent, manufacturers have continued to submit GRAS Notices as commercial production technologies evolved—from purified L-theanine, to tea-derived ingredients, to chemically synthesized materials, and now to fermentation-derived production methods.
This does not necessarily mean that each new manufacturing process requires an entirely new safety profile. In many cases, existing toxicological data and scientific literature may be highly relevant. However, manufacturers should still evaluate whether their commercial ingredient is sufficiently represented by existing GRAS precedent or whether additional regulatory support is appropriate.
For companies developing novel manufacturing technologies, changing suppliers, or commercializing proprietary ingredients, this evaluation can become one of the most important steps in establishing a defensible regulatory strategy.
Existing GRAS Precedent Does Not Automatically Apply to Every L-theanine Ingredient
The existence of multiple FDA GRAS Notices for L-theanine demonstrates that there is substantial regulatory precedent supporting certain commercial ingredients. However, one of the most common misconceptions is that these precedents automatically apply to every L-theanine ingredient available on the market.
That is not necessarily the case.
A GRAS conclusion is not attached to an ingredient name alone. Rather, it is based on the specific ingredient being evaluated and the conditions under which it will be used.
When determining whether an existing GRAS conclusion is applicable, manufacturers should consider whether their commercial ingredient aligns with the ingredient that was previously evaluated. Important questions include:
If the answer to these questions is yes, existing regulatory precedent may provide a strong foundation for the ingredient’s intended use.
However, when manufacturers introduce meaningful changes—such as a new manufacturing technology, significantly different specifications, higher use levels, or new food categories—it may be appropriate to perform an independent regulatory assessment to determine whether existing precedent remains applicable.
This evaluation becomes particularly important for companies developing proprietary manufacturing technologies or sourcing L-theanine from suppliers that utilize production methods different from those described in publicly available GRAS Notices.
Ultimately, the objective is not simply to identify an existing GRAS Notice with the words “L-theanine” on the cover. The objective is to determine whether qualified experts would conclude that the commercial ingredient being marketed is adequately represented by the available scientific evidence under its intended conditions of use.
Although L-theanine has precedent for use in numerous conventional foods, beverages often require additional regulatory consideration because they are consumed differently than many other food products.
Unlike confectionery or specialty snack products, beverages may be consumed several times throughout the day. Consumers may also obtain L-theanine from multiple dietary sources simultaneously, including conventional foods, dietary supplements, ready-to-drink beverages, powdered drink mixes, and brewed tea.
As a result, total daily dietary exposure—not simply the concentration in a single beverage—becomes an important component of the safety assessment.
Intended Use Levels
One of the first considerations is the amount of L-theanine delivered per serving.
Existing GRAS precedent includes intended use levels of up to 250 mg per serving for several food categories. However, manufacturers should also consider how consumers are expected to use the product in real-world settings.
For example, a beverage marketed as a single daily serving presents a different exposure scenario than a lightly flavored enhanced water intended for repeated consumption throughout the day.
Understanding anticipated consumer behavior helps ensure that estimated daily intake remains consistent with available safety data.
Cumulative Dietary Exposure
Consumers increasingly obtain functional ingredients from multiple products.
An individual may consume:
Although each individual product may fall within supported use levels, manufacturers should consider cumulative dietary exposure when evaluating the intended use of their ingredient.
Estimated Daily Intake (EDI) remains one of the most important components of a comprehensive GRAS assessment because it reflects how consumers are likely to encounter the ingredient across the broader food supply.
Combination with Other Functional Ingredients
L-theanine is frequently formulated alongside other functional ingredients, particularly caffeine.
This combination has become increasingly common in products positioned around “calm energy,” mental focus, or cognitive performance.
While existing GRAS precedent evaluates the safety of L-theanine itself, manufacturers should also consider the broader formulation during product development.
Depending on the product, this may include evaluating:
Although combining lawful food ingredients does not automatically require a new GRAS conclusion, manufacturers should consider whether the finished formulation introduces new exposure scenarios or other safety considerations beyond those evaluated for the individual ingredient.
Product Stability
Beverages also present formulation challenges that extend beyond regulatory compliance.
Manufacturers should evaluate how L-theanine performs throughout processing and the product’s intended shelf life.
Factors that may influence product performance include:
While these considerations are primarily formulation issues, they also help ensure that consumers receive a product that remains consistent with the ingredient evaluated during the safety assessment.
Whether relying on existing regulatory precedent or preparing an independent GRAS conclusion, a comprehensive assessment follows a structured scientific process.
Although every ingredient is unique, the overall framework is generally similar.
1. Ingredient Characterization
The assessment begins by defining exactly what substance is being evaluated.
This typically includes:
Because GRAS conclusions apply to a specific commercial ingredient, a clear understanding of ingredient identity forms the foundation of the entire assessment.
2. Intended Conditions of Use
The next step defines precisely how the ingredient will be used.
This includes:
These intended conditions establish the basis for both dietary exposure modelling and the subsequent safety evaluation.
3. Dietary Exposure Assessment
A comprehensive GRAS assessment estimates how much of the ingredient consumers are expected to ingest.
Exposure modelling generally considers:
Rather than evaluating a single product in isolation, the objective is to understand anticipated intake across the overall diet.
This exposure assessment is particularly important for functional ingredients that may appear in numerous foods and beverages simultaneously.
4. Safety Evaluation
The safety assessment integrates all available scientific evidence relevant to the ingredient.
Depending on the ingredient and intended use levels, this may include:
The objective is to determine whether qualified experts would generally recognize the ingredient as safe under the proposed conditions of use.
5. Expert Review and GRAS Conclusion
Finally, the available evidence is compiled into a comprehensive GRAS dossier.
Qualified experts review the scientific evidence, evaluate whether the intended use is generally recognized as safe, and reach an independent conclusion.
Depending on the manufacturer’s regulatory strategy, the conclusion may remain as an independent (self-) GRAS determination or be submitted to FDA through the voluntary GRAS Notification Program.
In either case, a well-prepared GRAS assessment provides manufacturers with a documented scientific rationale supporting the lawful use of the ingredient in conventional foods.
Because L-theanine is widely used throughout the food and dietary supplement industries, several regulatory misconceptions continue to circulate.
“FDA approved L-theanine.”
Not exactly.
FDA does not “approve” ingredients through the GRAS Notification Program. Instead, FDA may respond that it has no questions regarding a notifier’s conclusion that an ingredient is GRAS under its intended conditions of use.
That distinction is important because responsibility for ensuring the ingredient remains safe and lawfully marketed continues to rest with the manufacturer.
“Every L-theanine ingredient is automatically GRAS.”
No.
Existing GRAS precedent applies to specific commercial ingredients evaluated under specific conditions of use.
Manufacturing process, specifications, purity, intended food categories, use levels, and dietary exposure all influence whether existing precedent adequately supports another commercial ingredient.
“Natural L-theanine and synthetic L-theanine are regulated differently.”
Not necessarily.
The GRAS framework focuses on the commercial ingredient being evaluated rather than whether consumers perceive it as “natural” or “synthetic.”
As demonstrated by multiple GRAS Notices, FDA has reviewed L-theanine produced using different manufacturing technologies. The important question is whether the scientific evidence adequately supports the safety of the ingredient under its intended conditions of use.
“If my supplier says the ingredient is GRAS, I’m finished.”
Supplier documentation is often an important part of the regulatory evaluation, but it does not automatically establish that a finished food or beverage is adequately supported.
Manufacturers should still evaluate whether:
L-theanine has one of the more established regulatory histories among functional beverage ingredients.
Multiple FDA GRAS Notices have supported its use in conventional foods and beverages, including applications in fruit drinks, sports beverages, bottled water, teas, and other products under specified conditions of use.
However, these notices should not be interpreted as blanket authorization for every commercial L-theanine ingredient.
Instead, manufacturers should evaluate whether their ingredient aligns with existing regulatory precedent by considering:
As manufacturing technologies continue to evolve—including synthetic and fermentation-derived production methods—regulatory assessments remain an important part of bringing innovative ingredients to market.
Understanding these considerations early in product development can help manufacturers establish a scientifically defensible regulatory strategy while reducing uncertainty later in commercialization.
Whether you are incorporating L-theanine into a new functional beverage, evaluating a proprietary manufacturing process, or determining whether existing GRAS precedent applies to your commercial ingredient, developing an appropriate regulatory strategy early in product development can save significant time and resources.
dicentra’s regulatory scientists and toxicologists work with ingredient manufacturers, beverage companies, and food innovators to evaluate the applicability of existing GRAS precedent and identify the most appropriate regulatory pathway for their products.
Our services include:
With more than two decades of experience supporting food ingredient innovation, dicentra helps manufacturers develop scientifically robust, commercially practical regulatory strategies that facilitate successful entry into the U.S. market. Whether your L-theanine is extracted from tea, chemically synthesized, produced through fermentation, or incorporated into a next-generation functional beverage, our team can help determine whether existing GRAS precedent supports your product—or whether additional regulatory work may be appropriate.
Contact us today for support bringing your L-theanine product to market.